In this review
Emerging robotic systems
Increased de novo metastatic disease presentations
PROfound trial, and what’s new in targeted therapies
177lutetium-PSMA-617 for metastatic CRPC
Genomic biomarkers in active surveillance for prostate cancer
Theranostics: latest Australian data using actinium
PSMA PET for primary diagnosis and staging
Treatment of the primary in the oligometastatic setting
Selecting the right patient for metastatic directed therapy
Pelvic lymph-node dissection in the PSMA PET era
Please login below to download this issue (PDF)